{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:09:12Z","timestamp":1792238952305,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2021YFC2500900, 2021YFC2500904, and 2021YFC2500905"],"award-info":[{"award-number":["2021YFC2500900, 2021YFC2500904, and 2021YFC2500905"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021LSW006"],"award-info":[{"award-number":["ZR2021LSW006"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15322-2","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T08:56:34Z","timestamp":1764320194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The predictive value of intratumoral tertiary lymphoid structures on the response to immunotherapy in cancer patients: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Jian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanpeng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"1","key":"15322_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"15322_CR2","doi-asserted-by":"publisher","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","volume":"8","author":"J Qi","year":"2023","unstructured":"Qi J, Li M, Wang L, Hu Y, Liu W, Long Z, et al. National and subnational trends in cancer burden in China, 2005-20: an analysis of National mortality surveillance data. Lancet Public Health. 2023;8(12):e943\u201355.","journal-title":"Lancet Public Health"},{"issue":"8","key":"15322_CR3","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807\u201321.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"15322_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020;37(4):443\u201355.","journal-title":"Cancer Cell"},{"key":"15322_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","volume":"81","author":"LA Emens","year":"2017","unstructured":"Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116\u201329.","journal-title":"Eur J Cancer"},{"issue":"6349","key":"15322_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313.","journal-title":"Science"},{"issue":"4","key":"15322_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","volume":"22","author":"JC Dudley","year":"2016","unstructured":"Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22(4):813\u201320.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"15322_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0864-3","volume":"17","author":"M Yi","year":"2018","unstructured":"Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, et al. Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors. Mol Cancer. 2018;17(1):129.","journal-title":"Mol Cancer"},{"key":"15322_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101375","volume":"20","author":"J Cao","year":"2022","unstructured":"Cao J, Yang X, Chen S, Wang J, Fan X, Fu S, et al. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: a meta-analysis and bioinformatics analysis. Transl Oncol. 2022;20:101375.","journal-title":"Transl Oncol"},{"key":"15322_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.","journal-title":"Pharmacol Ther"},{"issue":"16","key":"15322_CR11","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921\u20135.","journal-title":"Curr Biol"},{"issue":"9","key":"15322_CR12","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1158\/1078-0432.CCR-21-1130","volume":"28","author":"M Lauss","year":"2022","unstructured":"Lauss M, Donia M, Svane IM, J\u00f6nsson G. B cells and tertiary lymphoid structures: friends or foes in cancer immunotherapy? Clin Cancer Res. 2022;28(9):1751\u20138.","journal-title":"Clin Cancer Res"},{"issue":"6576","key":"15322_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022;375(6576):eabf9419.","journal-title":"Science"},{"issue":"7791","key":"15322_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549\u201355.","journal-title":"Nature"},{"issue":"7","key":"15322_CR15","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","volume":"24","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, et al. A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018;24(7):994\u20131004.","journal-title":"Nat Med"},{"key":"15322_CR16","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"issue":"15","key":"15322_CR17","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283(15):2008\u201312.","journal-title":"JAMA"},{"issue":"9","key":"15322_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"15322_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"issue":"7791","key":"15322_CR20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561\u20135.","journal-title":"Nature"},{"key":"15322_CR21","doi-asserted-by":"crossref","unstructured":"Chen T, Cao Z, Sun Y, Huang J, Shen S, Jin Y, et al. Neoadjuvant chemoimmunotherapy increases tumor immune lymphocytes infiltration in resectable non-small cell lung cancer. Ann Surg Oncol. 2023;30(12):7549\u20137560.","DOI":"10.1245\/s10434-023-14123-w"},{"issue":"8","key":"15322_CR22","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","volume":"29","author":"TR Cottrell","year":"2018","unstructured":"Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018;29(8):1853\u201360.","journal-title":"Ann Oncol"},{"key":"15322_CR23","doi-asserted-by":"crossref","unstructured":"Gavrielatou N, Fortis E, Spathis A, Anastasiou M, Economopoulou P, Foukas GRP et al. B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 Inhibition in head and neck squamous cell carcinoma. Annals Oncology: Official J Eur Soc Med Oncol. 2024;35(4):340\u2013350.","DOI":"10.1016\/j.annonc.2023.12.011"},{"issue":"6","key":"15322_CR24","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41591-022-01821-3","volume":"28","author":"A Italiano","year":"2022","unstructured":"Italiano A, Bessede A, Pulido M, Bompas E, Piperno-Neumann S, Chevreau C, et al. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nat Med. 2022;28(6):1199\u2013206.","journal-title":"Nat Med"},{"key":"15322_CR25","doi-asserted-by":"crossref","unstructured":"Komura K, Tokushige S, Ishida M, Hirosuna K, Yamazaki S, Nishimura K, et al. Tertiary lymphoid structure and neutrophil\u2013lymphocyte ratio coordinately predict outcome of pembrolizumab. Cancer Sci. 2023;114(12):4622\u20134631.","DOI":"10.1111\/cas.15976"},{"issue":"1","key":"15322_CR26","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1038\/s41467-022-30569-0","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu J, Wang Y, Tian Z, Lin Y, Li H, Zhu Z, et al. Multicenter phase II trial of camrelizumab combined with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nat Commun. 2022;13(1):3011.","journal-title":"Nat Commun"},{"key":"15322_CR27","doi-asserted-by":"crossref","unstructured":"Mori T, Tanaka H, Deguchi S, Yamakoshi Y, Miki Y, Yoshii M, et al. Clinical efficacy of nivolumab is associated with tertiary lymphoid structures in surgically resected primary tumors of recurrent gastric cancer. PLoS On e. 2022 Jan 7;17(1):e0262455.","DOI":"10.1371\/journal.pone.0262455"},{"issue":"5","key":"15322_CR28","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1111\/cas.14888","volume":"112","author":"T Mori","year":"2021","unstructured":"Mori T, Tanaka H, Suzuki S, Deguchi S, Yamakoshi Y, Yoshii M, et al. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer. Cancer Sci. 2021;112(5):1746\u201357.","journal-title":"Cancer Sci"},{"key":"15322_CR29","doi-asserted-by":"crossref","unstructured":"Shang T, Jiang T, Lu T, Wang H, Cui X, Pan Y, et al. Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma. Front Immunol. 2023 10;14:1166497.","DOI":"10.3389\/fimmu.2023.1166497"},{"key":"15322_CR30","doi-asserted-by":"crossref","unstructured":"Sun X, Liu W, Sun L, Mo H, Feng Y, Wu X, et al. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2022;10(11):e005531.","DOI":"10.1136\/jitc-2022-005531"},{"issue":"8","key":"15322_CR31","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke L, Brunet M, Gu\u00e9gan JP, Rey C, Bougouin A, Cousin S, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer. 2021;2(8):794\u2013802.","journal-title":"Nat Cancer"},{"issue":"5","key":"15322_CR32","first-page":"453","volume":"50","author":"JC Wei","year":"2021","unstructured":"Wei JC, Yuan P, Ling Y, Li L, Guo CY, Guo L, et al. Histopathological features of squamous cell carcinoma of lung neoadjuvant immunotherapy focusing on responses. Zhonghua Bing Li Xue Za zhi\u2009=\u2009Chinese. J Pathol. 2021;50(5):453\u20137.","journal-title":"J Pathol"},{"key":"15322_CR33","doi-asserted-by":"publisher","first-page":"1244256","DOI":"10.3389\/fimmu.2023.1244256","volume":"14","author":"F Xu","year":"2023","unstructured":"Xu F, Zhu H, Dong Y, Li L, Liu N, Yuan S. Combined inflammatory parameters and tertiary lymphoid structure predict prognosis in patients with resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy. Front Immunol. 2023;14:1244256.","journal-title":"Front Immunol"},{"key":"15322_CR34","doi-asserted-by":"crossref","unstructured":"Xu F, Zhu H, Xiong D, Wang K, Dong Y, Li L, et al. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: a retrospective study. Thorac Cancer. 2024;15(2):172\u2013181.","DOI":"10.1111\/1759-7714.15175"},{"issue":"12","key":"15322_CR35","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","volume":"26","author":"N van Dijk","year":"2020","unstructured":"van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020;26(12):1839\u201344.","journal-title":"Nat Med"},{"key":"15322_CR36","doi-asserted-by":"publisher","first-page":"1063711","DOI":"10.3389\/fimmu.2022.1063711","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Wu S. Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response. Front Immunol. 2022;13:1063711.","journal-title":"Front Immunol"},{"issue":"6","key":"15322_CR37","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41423-020-0457-0","volume":"17","author":"L Munoz-Erazo","year":"2020","unstructured":"Munoz-Erazo L, Rhodes JL, Marion VC, Kemp RA. Tertiary lymphoid structures in cancer - considerations for patient prognosis. Cell Mol Immunol. 2020;17(6):570\u20135.","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"15322_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1378844","volume":"7","author":"F Posch","year":"2018","unstructured":"Posch F, Silina K, Leibl S, M\u00fcndlein A, Moch H, Siebenh\u00fcner A, et al. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. Oncoimmunology. 2018;7(2):e1378844.","journal-title":"Oncoimmunology"},{"issue":"12","key":"15322_CR39","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/ni.3290","volume":"16","author":"S Finkin","year":"2015","unstructured":"Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol. 2015;16(12):1235\u201344.","journal-title":"Nat Immunol"},{"issue":"4","key":"15322_CR40","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jord\u00e3o MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11(4):933\u201359.","journal-title":"Cancer Discov"},{"issue":"5","key":"15322_CR41","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.jcmgh.2021.06.023","volume":"12","author":"FR Delvecchio","year":"2021","unstructured":"Delvecchio FR, Fincham REA, Spear S, Clear A, Roy-Luzarraga M, Balkwill FR, et al. Pancreatic cancer chemotherapy is potentiated by induction of tertiary lymphoid structures in mice. Cell Mol Gastroenterol Hepatol. 2021;12(5):1543\u201365.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"8","key":"15322_CR42","doi-asserted-by":"publisher","first-page":"7194","DOI":"10.1021\/acsnano.2c09619","volume":"17","author":"Z Wen","year":"2023","unstructured":"Wen Z, Liu H, Qiao D, Chen H, Li L, Yang Z, et al. Nanovaccines fostering tertiary lymphoid structure to attack mimicry nasopharyngeal carcinoma. ACS Nano. 2023;17(8):7194\u2013206.","journal-title":"ACS Nano"},{"issue":"6","key":"15322_CR43","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cell.2020.02.015","volume":"180","author":"Y Lu","year":"2020","unstructured":"Lu Y, Zhao Q, Liao JY, Song E, Xia Q, Pan J, et al. Complement signals determine opposite effects of B cells in Chemotherapy-Induced immunity. Cell. 2020;180(6):1081\u2013e9724.","journal-title":"Cell"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15322-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15322-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15322-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T05:33:25Z","timestamp":1767072805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15322-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15322"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15322-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a systematic review and meta-analysis. All analyses were based on previous published studies, thus no ethical approval and patient consent are required, and performing the research in accordance with the Helsinki Declaration is not applicable to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1935"}}